Tactile Medical makes and sells at-home medical devices for treating chronic conditions, primarily lymphedema and airway clearance diseases. Lymphedema — chronic swelling caused by a damaged lymphatic system, commonly resulting from cancer treatment — accounts for roughly 84% of revenue. Tactile's core lymphedema products are pneumatic compression devices (PCDs), wearable garments that inflate and deflate to move fluid out of swollen tissue, allowing patients to treat themselves at home rather than visiting a specialized clinic. The flagship product, Flexitouch Plus, treats complex lymphedema across the full body, while the newer Nimbl platform targets simpler, limb-focused cases. The remaining ~16% of revenue comes from AffloVest, a portable, battery-powered vest that loosens mucus in patients with bronchiectasis, cystic fibrosis, and similar respiratory conditions. Tactile uses a direct-to-patient model for lymphedema: account managers call on physicians and therapists to generate referrals, and Tactile then handles insurance authorization, billing, and ships directly to the patient's home — capturing both manufacturer and distributor margins. AffloVest is sold through DME distributors, who handle fulfillment and billing. Most revenue is paid by insurers, with private insurers, Medicare, and the VA covering the majority of costs. Key revenue drivers include referral volume, insurance coverage policies, and product mix between advanced and basic PCDs. Tactile is investing in AI-based order intake, e-prescribing tools, and patient engagement software to reduce administrative friction and patient drop-off during the authorization process.